Tyme Inc. (TYME) Reports In-Line Q3 EPS

Tyme Inc. (NASDAQ: TYME) reported Q3 EPS of ($0.08), in-line with the analyst estimate of ($0.08).

Mr. Steven Hoffman, Chairman and Chief Executive Officer of Tyme Technologies, Inc., stated, “Based on the broad support that we have received during the quarter from pancreatic physicians, patients, and patient advocacy groups, we are excited to advance SM-88 into the next stage of pivotal trials.”

“Pancreatic Cancer is a devastating disease, predicted to be the second cause of cancer death by 2030,”1 said Martin E. Fernandez-Zapico, MD, a Professor of Medicine and Pharmacology at the Department of Oncology at the Mayo Clinic. “In advanced pancreatic cancers, there is an urgent need for new treatment options. SM-88 represents a new therapeutic approach aimed at disrupting the tumor metabolic program."

• TYME’s novel metabolic-based investigational cancer therapy, SM-88, demonstrated encouraging results and a well-tolerated safety profile in a preliminary analysis from a Phase II study of patients with advanced pancreatic cancer
• TYME is in discussions with the FDA regarding pivotal trial design for third-line pancreatic cancer based on preliminary results from the TYME-88-Panc Phase II trial
• TYME partners with the Pancreatic Cancer Action Network’s (PanCAN) “Precision Promise(SM)” program to advance SM-88 pivotal paths for first- and second-line treatment in patients with pancreatic cancer
• Initiation of investigator-sponsored Phase II trial using SM-88 as monotherapy in patients with previously-treated high-risk sarcoma expected in 1Q19
• TYME expands senior leadership team and research capabilities
• Presentation of data from clinical trial evaluating SM-88 in biochemically recurrent prostate cancer scheduled for Thursday, February 14th at American Society of Clinical Oncology’s (ASCO) 2019 Genitourinary Cancers Symposium

For earnings history and earnings-related data on Tyme Inc. (TYME) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15